2 studies found for:    15483010 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL
Condition: B-cell Non-Hodgkin Lymphoma
Interventions: Drug: 0.5 mg/m2 DI-Leu16-IL2;   Drug: 1.0 mg/m2 DI-Leu16-IL2;   Drug: 2.0 mg/m2 DI-Leu16-IL2;   Drug: 4.0 mg/m2 DI-Leu16-IL2;   Drug: 6.0 mg/m2 DI-Leu16-IL2;   Drug: 8.0 mg/m2 DI-Leu16-IL2;   Drug: 10.0 mg/m2 DI-Leu16-IL2
2 Not yet recruiting An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Condition: B-cell Non-Hodgkin Lymphoma
Intervention: Drug: DI-Leu16-IL2

Indicates status has not been verified in more than two years